Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway

World Journal of Gastroenterology

Volumn 15, Issue 44, 2009, Pages 5541-5548

  Li, Guo Qing ^a   Xie, Juan ^a   Lei, Xiao Yong ^a   Zhang, Li ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Cell cycle; Cyclin D1; Gastric cancer; Macrophage migration inhibitory factor; PI3K Akt; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

EID: 74049091354     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.5541     Document Type: Article

References (38)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362
2. Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006; 12: 3237-3242
3. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005; 81: 419-424
4. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592
5. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150
6. Sutter AP, Fechner H. Gene therapy for gastric cancer: is it promising? World J Gastroenterol 2006; 12: 380-387
7. Leng L, Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2005; 33: S475-S477
8. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008; 75: 127-133
9. Shun CT, Lin JT, Huang SP, Lin MT, Wu MS. Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J Gastroenterol 2005; 11: 3767-3771
10. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia HH. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 2006; 55: 797-802
11. Camlica H, Duranyildiz D, Oguz H, Oral EN, Yasasever V. The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res 2008; 14: 79-83
12. Liu L, Ji C, Chen J, Li Y, Fu X, Xie Y, Gu S, Mao Y. A global genomic view of MIF knockdown-mediated cell cycle arrest. Cell Cycle 2008; 7: 1678-1692
13. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007; 98: 629-635
14. Zheng JY, Wang WZ, Li KZ, Guan WX, Yan W. Effect of p27(KIP1) on cell cycle and apoptosis in gastric cancer cells. World J Gastroenterol 2005; 11: 7072-7077
15. Ge JR, Ren GP, Yao HP. [Expression of cyclin D1 and p27kip1 in renal cell carcinoma and its significance] Zhejiang Daxue Xuebao Yixueban 2007; 36: 483-487
16. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603
17. Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, Byun DS, Chae KS, Lee BH, Chun HS, Lee KY, Kim HJ, Chi SG. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 2008; 135: 2030-2042, 2042. e1-e3
18. Kim JH, Go HY, Jin DH, Kim HP, Hong MH, Chung WY, Park JH, Jang JB, Jung H, Shin YC, Kim SH, Ko SG. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett 2008; 265: 197-205
19. Kim N, Kim CH, Ahn DW, Lee KS, Cho SJ, Park JH, Lee MK, Kim JS, Jung HC, Song IS. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 2009; 24: 480-487
20. Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 2007; 26: 281-285
21. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800
22. Mitchell RA. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 2004; 16: 13-19
23. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006; 18: 688-703
24. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B, Bernhagen J. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046-5059
25. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 2005; 17: 225-236
26. Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006; 11: 1164-1188
27. Johansson M, Persson JL. Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem 2008; 8: 723-731
28. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6: 24
29. Belletti B, Nicoloso MS, Schiappacassi M, Chimienti E, Berton S, Lovat F, Colombatti A, Baldassarre G. p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem 2005; 12: 1589-1605
30. Hershko DD, Shapira M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 2006; 107: 668-675
31. Lecanda J, Parekh TV, Gama P, Lin K, Liarski V, Uretsky S, Mittal K, Gold LI. Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium. Cancer Res 2007; 67: 1007-1018
32. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6: 661-672
33. Lahav-Baratz S, Ben-Izhak O, Sabo E, Ben-Eliezer S, Lavie O, Ishai D, Ciechanover A, Dirnfeld M. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol Hum Reprod 2004; 10: 567-572
34. Yu BH, Zhou XY. [Advances on PI3K/Akt/mTOR signalling pathway in malignancies] Zhonghua Binglixue Zazhi 2005; 34: 674-676
35. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008; 8: 27-36
36. Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005; 43: 1133-1139
37. Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato MC, Marrelli D, Cevenini G, Tosi P. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch 2008; 453: 449-455
38. Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J, Chen Y, Wang X, Liu J, Guo X, Chen Z, Qiao T, Fan D. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J 2007; 21: 2247-2256